BRPI0408749A - usos de um agente capaz de bloquear, inibir, ou melhorar a atividade mediada por vegf e de uma molécula capaz de inibir a expressão ou a atividade de vegf, e, artigo de manufatura - Google Patents

usos de um agente capaz de bloquear, inibir, ou melhorar a atividade mediada por vegf e de uma molécula capaz de inibir a expressão ou a atividade de vegf, e, artigo de manufatura

Info

Publication number
BRPI0408749A
BRPI0408749A BRPI0408749-6A BRPI0408749A BRPI0408749A BR PI0408749 A BRPI0408749 A BR PI0408749A BR PI0408749 A BRPI0408749 A BR PI0408749A BR PI0408749 A BRPI0408749 A BR PI0408749A
Authority
BR
Brazil
Prior art keywords
vegf
activity
inhibiting
blocking
article
Prior art date
Application number
BRPI0408749-6A
Other languages
English (en)
Inventor
Mark W Sleeman
Stanley J Wiegand
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BRPI0408749A publication Critical patent/BRPI0408749A/pt
Publication of BRPI0408749B1 publication Critical patent/BRPI0408749B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"USOS DE UM AGENTE CAPAZ DE BLOQUEAR, INIBIR, OU MELHORAR A ATIVIDADE MEDIADA POR VEGF E DE UMA MOLéCULA CAPAZ DE INIBIR A EXPRESSãO OU A ATIVIDADE DE VEGF, E, ARTIGO DE MANUFATURA". Métodos de tratar diabetes em mamíferos, particularmente humanos, pelo bloqueio ou pela inibição da atividade mediada por VEGF. Um inibidor preferido de atividade mediada por VEGF é um antagonista de VEGF tal como um capturador de VEGF capaz de ligar e bloquear VEGF.
BRPI0408749A 2003-03-28 2004-03-26 uso do antagonista de vegf vegfr1r2-fc delta c1(a) BRPI0408749B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45879003P 2003-03-28 2003-03-28
PCT/US2004/009246 WO2004087206A2 (en) 2003-03-28 2004-03-26 Methods of treating diabetes by blocking vegf-mediated activity

Publications (2)

Publication Number Publication Date
BRPI0408749A true BRPI0408749A (pt) 2006-03-28
BRPI0408749B1 BRPI0408749B1 (pt) 2016-10-04

Family

ID=33131825

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408749A BRPI0408749B1 (pt) 2003-03-28 2004-03-26 uso do antagonista de vegf vegfr1r2-fc delta c1(a)

Country Status (17)

Country Link
US (1) US7052691B2 (pt)
EP (1) EP1608685B1 (pt)
JP (2) JP4730909B2 (pt)
AT (1) ATE354592T1 (pt)
AU (1) AU2004226417B2 (pt)
BR (1) BRPI0408749B1 (pt)
CA (1) CA2519787C (pt)
CY (1) CY1106530T1 (pt)
DE (1) DE602004004883T2 (pt)
DK (1) DK1608685T3 (pt)
ES (1) ES2278333T3 (pt)
HK (1) HK1080092A1 (pt)
MX (1) MXPA05008972A (pt)
PL (1) PL1608685T3 (pt)
PT (1) PT1608685E (pt)
SI (1) SI1608685T1 (pt)
WO (1) WO2004087206A2 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007001241A (es) 2004-07-30 2007-07-11 Regeneron Pharma Metodos para tratar diabetes tipo i mediante el bloqueo de la actividad mediada de vegf.
PT1861116E (pt) 2005-03-25 2015-11-04 Regeneron Pharma Formulações de antagonista do vegf
CN101478949A (zh) 2006-06-16 2009-07-08 瑞泽恩制药公司 适合玻璃体内施用的vegf拮抗剂的制剂
ES2345596B1 (es) * 2009-03-26 2011-07-13 Fundacion Progreso Y Salud Composicion para la prevencion o el tratamiento de la diabetes mellitus.
US20100330098A1 (en) * 2009-06-29 2010-12-30 Kuo Calvin J Methods to regulate glucose metabolism
KR20220097542A (ko) 2011-01-13 2022-07-07 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
AU2015208482B2 (en) 2014-01-25 2017-02-02 Chengdu Kanghong Biotechnologies Co., Ltd. Fusion protein inhibiting angiogenesis or growth and use thereof
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3170005B1 (en) 2014-07-18 2019-04-10 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
IL290457B1 (en) 2015-12-30 2024-10-01 Kodiak Sciences Inc Antibodies and their conjugates
ITUB20169928A1 (it) * 2016-01-12 2017-07-12 Medical And Biotechnological Services In Sigla M B S Srl Formulazioni farmaceutiche per il trattamento del diabete
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021226444A2 (en) 2020-05-08 2021-11-11 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9410533D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd In situ hybridisation and immuno-Chemical localisation of a growth factor
CA2372053C (en) * 1999-04-28 2008-09-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
JP4723140B2 (ja) * 1999-06-08 2011-07-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 改善された薬物動態特性を有する改変キメラポリペプチド
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases

Also Published As

Publication number Publication date
JP2006521397A (ja) 2006-09-21
EP1608685B1 (en) 2007-02-21
DE602004004883D1 (de) 2007-04-05
HK1080092A1 (en) 2006-04-21
DE602004004883T2 (de) 2007-11-15
CA2519787C (en) 2012-06-05
CA2519787A1 (en) 2004-10-14
AU2004226417B2 (en) 2009-01-22
US20040213787A1 (en) 2004-10-28
CY1106530T1 (el) 2012-01-25
MXPA05008972A (es) 2005-11-04
PL1608685T3 (pl) 2007-07-31
ATE354592T1 (de) 2007-03-15
WO2004087206A2 (en) 2004-10-14
JP4730909B2 (ja) 2011-07-20
US7052691B2 (en) 2006-05-30
ES2278333T3 (es) 2007-08-01
EP1608685A2 (en) 2005-12-28
PT1608685E (pt) 2007-05-31
DK1608685T3 (da) 2007-06-11
SI1608685T1 (sl) 2007-08-31
WO2004087206A3 (en) 2004-12-16
BRPI0408749B1 (pt) 2016-10-04
AU2004226417A1 (en) 2004-10-14
JP2011037894A (ja) 2011-02-24

Similar Documents

Publication Publication Date Title
BRPI0408749A (pt) usos de um agente capaz de bloquear, inibir, ou melhorar a atividade mediada por vegf e de uma molécula capaz de inibir a expressão ou a atividade de vegf, e, artigo de manufatura
BR0308854A (pt) Benzazolas substituìdas e seus usos como inibidoras de quinase raf
EA200600689A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов raf киназы
CY1109906T1 (el) Παραγωγα c3-kyano εποθιλονης
UA107783C2 (en) Isoindoline compounds for use in treating cancer
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
ATE416177T1 (de) Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer
ATE520668T1 (de) Sigmarezeptor-inhibitoren
MXPA05010819A (es) Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
PH12013500578A1 (en) Substituted dihydropyrazolones for treating cardiovascular and haematological diseases
TW200714604A (en) Substituted heterocycles and the uses thereof
DK1309592T3 (da) Substituerede pyrazoler
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
BRPI0511139B8 (pt) compostos que inibem quinase aurora e composição farmacêutica contendo os mesmos
NO20071428L (no) Kombinasjon inneholdende ZD6474 og Imatinib
DE60223262D1 (de) Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
WO2003002114A3 (en) Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis
EA200800755A1 (ru) Ikk ингибиторы, предназначенные для лечения эндометриоза
EA200900571A1 (ru) Композиции chk1 ингибиторов
BR0214481A (pt) Método e composição para potenciação de um analgésico opiáceo
NO20054361L (no) Benzensylfonamidderivater, fremgangsmate for fremstilling og anvendelse derav for behandlig av smerte
BRPI0519355A2 (pt) compostos para tratamento contra flaviviridae
EA200800766A1 (ru) Ингибиторы pi3k для лечения эндометриоза
ATE507218T1 (de) Benzodiazepin-derivate als rock-kinasen hemmer

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/10/2016, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: REFERENTE AO DESPACHO 21.6 PUBLICADO NA RPI 2559 DE 2020-01-21